Ivonescimab Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

Total Trials

Recruiting

Completed

17,325

Total Enrollment

States

Ivonescimab Evidence & Publications

79 peer-reviewed publications + per-arm primary-outcome data from 0 pivotal trials.

See published evidence →

Ivonescimab Clinical Trials

Sortable list of all 87 Ivonescimab trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

What Is Ivonescimab?

Ivonescimab is an investigational medication being studied for various cancers. It is a specially engineered antibody designed for cancer immunotherapy. Ivonescimab works by attaching to two key targets: PD-1 (Programmed Death-1) and VEGF-A (Vascular Endothelial Growth Factor A). By binding to VEGF, it aims to interfere with tumor angiogenesis, which is the formation of new blood vessels that tumors need to grow and spread.

This drug is currently under investigation in clinical trials, with no mention of FDA approval in the provided data. Across 87 clinical trials, Ivonescimab has enrolled a total of 17,325 participants. The earliest trial began on 2010-01-05, and the latest is projected to conclude on 2026-05-04. Currently, 47 trials are actively recruiting participants.

Ivonescimab is being investigated for conditions such as Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, and Head and Neck Squamous Cell Carcinoma. It is also being studied in various neoadjuvant therapy settings.

Uses and Conditions Under Study

Ivonescimab is being investigated as a potential treatment for a range of cancers, often in combination with other therapies. Clinical trials are exploring its efficacy and safety across several tumor types.

Lung Cancers: Ivonescimab is extensively studied for Non-Small Cell Lung Cancer (NSCLC). This includes 7 trials specifically for Non-Small Cell Lung Cancer, 4 for NSCLC, and another 3 for Non Small Cell Lung Cancer, totaling 14 trials. These studies aim to determine if Ivonescimab can help block cancer cell growth and improve outcomes in patients with advanced or metastatic NSCLC, including those with specific genomic alterations or resistance to prior immunotherapies.
Breast Cancers: The drug is also under investigation for breast cancer, with 3 trials for Breast Cancer and 2 for Breast Tumors. Some studies focus on challenging forms, such as triple-negative breast cancer (TNBC) with brain metastasis, where prognosis is often poor. Ivonescimab is being explored for its potential to slow cancer growth in these settings.
Other Solid Tumors: Ivonescimab is being studied in 4 trials for Pancreatic Cancer, a difficult-to-treat malignancy. Additionally, there are 3 trials for Head and Neck Squamous Cell Carcinoma and 2 trials for Metastatic Colorectal Cancer. These trials explore Ivonescimab's role in blocking tumor growth and improving treatment responses in these advanced cancers.
Neoadjuvant Therapy: In 4 trials, Ivonescimab is being evaluated as a neoadjuvant therapy, which is treatment given before the main treatment (like surgery) to shrink tumors. This approach aims to improve surgical outcomes and reduce the risk of cancer recurrence.

Dosing

Ivonescimab is an investigational drug typically administered as an intravenous (IV) infusion. As an antibody, it is delivered directly into a vein, often in combination with other chemotherapy agents or novel therapies.

Clinical trials have explored various dosing regimens and combinations. Specific strengths of Ivonescimab studied include 10 mg/kg and 20 mg/kg. These doses are administered in different treatment arms, often alongside other drugs such as carboplatin/pemetrexed, gemcitabine, sacituzumab govitecan, or various chemotherapy regimens like FOLFIRI or mFOLFOX6.

Ivonescimab has been studied as monotherapy in some cohorts, such as in patients with advanced non-small cell lung cancer or incurable salivary gland carcinomas. It is also being investigated in combination with other agents, including targeted therapies like osimertinib or antibody-drug conjugates (ADCs) such as Dato-DXd or Disitamab Vedotin. The exact dosing schedule (e.g., frequency and duration) is determined by the specific clinical trial protocol and the patient's condition, as it is still under investigation. There is no information provided regarding specific pediatric dosing, with studies focusing on adult cancer populations.

Side Effects

The most common side effect reported in clinical trials for Ivonescimab was anemia, affecting 29% of patients taking the drug, compared to 14% of patients on placebo. Other common side effects included:

Leukopenia (low white blood cell count): 27% of patients taking Ivonescimab experienced this, compared to 1% on placebo.
Neutropenia (low neutrophil count): 26% of patients taking Ivonescimab experienced this, compared to 1% on placebo.
Increased aspartate aminotransferase (AST), an indicator of liver function: 25% of patients taking Ivonescimab experienced this, compared to 10% on placebo.
Increased alanine aminotransferase (ALT), another indicator of liver function: 24% of patients taking Ivonescimab experienced this, compared to 10% on placebo.
Hypoalbuminemia (low albumin levels): 24% of patients taking Ivonescimab experienced this, compared to 12% on placebo.
Proteinuria (protein in the urine): 23% of patients taking Ivonescimab experienced this, compared to 10% on placebo.
Thrombocytopenia (low platelet count): 22% of patients taking Ivonescimab experienced this, compared to 1% on placebo.

Clinical Trial Results

Non-Small Cell Lung Cancer (NSCLC) – EGFR-Mutated, Post-EGFR-TKI Treatment

In a Phase 3 study (NCT05130552) involving patients with locally advanced or metastatic EGFR-mutated NSCLC whose disease had progressed after prior EGFR-tyrosine kinase inhibitor (TKI) therapy, Ivonescimab combined with chemotherapy significantly improved outcomes compared to placebo plus chemotherapy. Patients receiving Ivonescimab had a median progression-free survival (PFS) of 10.3 months, meaning half of these patients lived at least this long without their cancer worsening. This was a substantial improvement compared to a median PFS of 6.0 months for patients on placebo plus chemotherapy. Ivonescimab reduced the risk of disease progression or death by 54% (Hazard Ratio: 0.46).

The objective response rate (ORR), which is the percentage of patients whose tumors shrank or disappeared, was also higher with Ivonescimab. 62.1% of patients on Ivonescimab achieved an objective response, compared to 36.2% on placebo. The median duration of response (DoR) was 9.8 months for Ivonescimab, versus 4.8 months for placebo.

Non-Small Cell Lung Cancer (NSCLC) – PD-L1 Positive, First-Line Treatment

A Phase 2 study (NCT04746924) in patients with advanced PD-L1 positive NSCLC who had not received prior systemic therapy showed that Ivonescimab combined with chemotherapy improved the objective response rate. 50.0% of patients treated with Ivonescimab plus chemotherapy achieved an objective response, compared to 35.7% of patients on placebo plus chemotherapy.

Ivonescimab also extended progression-free survival in this population, with a median PFS of 8.2 months, compared to 5.8 months for patients on placebo plus chemotherapy. This represented a 35% reduction in the risk of disease progression or death (Hazard Ratio: 0.65).

Other Advanced Cancers (Phase 1b/2 Study)

In a smaller, earlier-phase study (NCT04077717) evaluating Ivonescimab with chemotherapy in various advanced cancers, some promising results were observed:

NSCLC (PD-L1 positive, first-line): Among 38 patients, the ORR was 68.4%, with a median PFS of 15.2 months and a median DoR of 13.6 months.
NSCLC (PD-L1 positive, after anti-PD-1/PD-L1 therapy): Among 28 patients, the ORR was 42.9%, with a median PFS of 8.3 months and a median DoR of 7.9 months.
Hepatocellular Carcinoma (HCC, first-line): Among 18 patients, the ORR was 33.3%, with a median PFS of 7.2 months and a median DoR of 6.5 months.
Gastric Cancer (GC) / Gastroesophageal Junction Cancer (GEJC, first-line): Among 20 patients, the ORR was 40.0%, with a median PFS of 6.8 months and a median DoR of 6.1 months.

Currently Recruiting Trials

Ivonescimab is currently being investigated in numerous clinical trials across various cancer types, offering potential new treatment options. These studies aim to evaluate the safety and effectiveness of ivonescimab, often in combination with other therapies, for patients with advanced or metastatic cancers. Here are some of the trials actively seeking participants:

A Phase 1/2 study (NCT07535463) by Memorial Sloan Kettering Cancer Center is enrolling 53 participants with non-small cell lung cancer (NSCLC) that has spread to the brain, testing ivonescimab with chemotherapy and stereotactic radiosurgery.
Another Phase 1/2 trial (NCT07535437) by Memorial Sloan Kettering Cancer Center is for 66 people with EGFR-mutated NSCLC, combining ivonescimab with Dato-DXd or osimertinib.
For advanced/unresectable leiomyosarcoma, Memorial Sloan Kettering Cancer Center is conducting a Phase 2 study (NCT07516925) of ivonescimab monotherapy, targeting 20 participants.
PrECOG, LLC. is sponsoring a Phase

Ivonescimab Development Timeline

Clinical trial activity from 2010 to 2026.

2026

NCT07234877PHASE2not yet recruiting

Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets

158 enrolled

NCT07359456PHASE2not yet recruiting

Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases

130 enrolled

NCT07393555PHASE2not yet recruiting

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

117 enrolled

NCT07405190PHASE2not yet recruiting

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

46 enrolled

NCT07158489PHASE2not yet recruiting

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

47 enrolled

NCT07363408PHASE1not yet recruiting

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

NCT07226544PHASE2recruiting

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

31 enrolled

NCT07560124PHASE1/PHASE2not yet recruiting

A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer

286 enrolled

NCT07244978PHASE2not yet recruiting

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

49 enrolled

NCT07565389PHASE2not yet recruiting

Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

42 enrolled

NCT07412262PHASE2not yet recruiting

A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression

32 enrolled

NCT07264075PHASE3recruiting

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN

780 enrolled

NCT07535463PHASE1/PHASE2recruiting

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

53 enrolled

NCT07535437PHASE1/PHASE2recruiting

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

66 enrolled

NCT07516925PHASE2recruiting

A Study of Ivonescimab in People With Leiomyosarcoma

20 enrolled

NCT07057791PHASE2recruiting

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

60 enrolled

NCT07472478PHASE2not yet recruiting

Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)

32 enrolled

NCT06951646PHASE2recruiting

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

70 enrolled

NCT07339839PHASE1/PHASE2not yet recruiting

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

42 enrolled

NCT07374250PHASE2not yet recruiting

Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma

154 enrolled

NCT07381075PHASE2not yet recruiting

A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

120 enrolled

NCT07397338PHASE1/PHASE2recruiting

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

370 enrolled

2025

NCT07394218PHASE2recruiting

ctDNA-guided Treatment Decision-making

122 enrolled

NCT07244965PHASE2not yet recruiting

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

42 enrolled

NCT07241819PHASE2not yet recruiting

Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

66 enrolled

NCT06846346PHASE2recruiting

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

88 enrolled

NCT07228832PHASE3recruiting

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

600 enrolled

NCT07094685PHASE2recruiting

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

28 enrolled

NCT07204548PHASE2not yet recruiting

The IVO-LUNG Study

63 enrolled

NCT07245446PHASE2recruiting

A Study of Ivonescimab in First-Line ES-SCLC

180 enrolled

NCT07208773PHASE1/PHASE2recruiting

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

260 enrolled

NCT07229417PHASE2recruiting

IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma

29 enrolled

NCT07070466PHASE2recruiting

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

40 enrolled

NCT06529718PHASE2recruiting

Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

72 enrolled

NCT06848842PHASE2recruiting

Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

40 enrolled

NCT07162714PHASE2not yet recruiting

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

30 enrolled

NCT07064902PHASE2not yet recruiting

Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma

48 enrolled

NCT07095803PHASE2not yet recruiting

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

60 enrolled

NCT07086326PHASE2not yet recruiting

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

164 enrolled

NCT07038915PHASE2withdrawn

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

0 enrolled

NCT06959550PHASE2recruiting

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

90 enrolled

NCT07017673PHASE2recruiting

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

34 enrolled

NCT06913218PHASE1not yet recruiting

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

60 enrolled

NCT06980077PHASE2recruiting

Ivonescimab for the Treatment of Thymic Cancer

25 enrolled

NCT06928389PHASE3recruiting

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

536 enrolled

NCT06940518PHASE2recruiting

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

40 enrolled

NCT07188103PHASE2recruiting

Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma

37 enrolled

NCT07359040recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

80 enrolled

NCT06840834PHASE2recruiting

Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy

38 enrolled

NCT06977542PHASE2not yet recruiting

Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer

53 enrolled

NCT07009925PHASE2not yet recruiting

Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

38 enrolled

NCT07070479PHASE2recruiting

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

208 enrolled

NCT06953999PHASE3recruiting

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

999 enrolled

NCT06991491PHASE2not yet recruiting

Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)

29 enrolled

NCT06993025PHASE2not yet recruiting

Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies

30 enrolled

NCT06957561PHASE1/PHASE2not yet recruiting

Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

30 enrolled

NCT06790212PHASE2not yet recruiting

Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

168 enrolled

NCT06877650PHASE1/PHASE2recruiting

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

436 enrolled

NCT06925724PHASE2recruiting

A Study of Ivonescimab in People With Endometrial and Cervical Cancers

50 enrolled

NCT06868732PHASE1recruiting

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

288 enrolled

NCT06875076PHASE2recruiting

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

25 enrolled

NCT06814158PHASE2not yet recruiting

Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

57 enrolled

NCT06936488NAenrolling by invitation

A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer

35 enrolled

NCT06820762PHASE2not yet recruiting

Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study

40 enrolled

NCT06767514PHASE3recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

780 enrolled

NCT06805617PHASE2recruiting

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

35 enrolled

NCT06814067PHASE2not yet recruiting

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

80 enrolled

NCT06844422PHASE1/PHASE2recruiting

Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

37 enrolled

NCT06769971PHASE2recruiting

Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC

80 enrolled

NCT06672575PHASE1/PHASE2recruiting

A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

45 enrolled

NCT06760520PHASE2not yet recruiting

Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer

40 enrolled

NCT06766591NAnot yet recruiting

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

36 enrolled

2024

NCT06750952PHASE2not yet recruiting

Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial

24 enrolled

NCT06793332PHASE2recruiting

BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

39 enrolled

NCT06567314PHASE2recruiting

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

24 enrolled

NCT06489197PHASE2recruiting

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

30 enrolled

NCT06802666PHASE2recruiting

Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

45 enrolled

NCT06478043PHASE2not yet recruiting

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

54 enrolled

NCT06491472PHASE2recruiting

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

36 enrolled

NCT06444009PHASE2recruiting

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

90 enrolled

NCT06196697PHASE2recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

50 enrolled

NCT06375486PHASE2recruiting

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.

30 enrolled

2023

NCT05899608PHASE3recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

1,600 enrolled

NCT06145308PHASE2recruiting

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

2022

NCT05582499PHASE2recruiting

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

716 enrolled

NCT05184712PHASE3active not recruiting

Phase 3 Clinical Study of AK112 for NSCLC Patients

322 enrolled

2010

NCT01042379PHASE2recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

5,000 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Non-Small Cell Lung Cancer	NCT07412262	A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression	not yet recruiting	PHASE2	32
	NCT07535463	A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer	recruiting	PHASE1/PHASE2	53
	NCT07535437	A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer	recruiting	PHASE1/PHASE2	66
	NCT06928389	Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer	recruiting	PHASE3	536
	NCT07359040	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	recruiting	N/A	80
	NCT06767514	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1	recruiting	PHASE3	780
	NCT05899608	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients	recruiting	PHASE3	1,600
NSCLC	NCT07158489	Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC	not yet recruiting	PHASE2	47
	NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370
	NCT07086326	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	not yet recruiting	PHASE2	164
	NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	not yet recruiting	NA	36
Neoadjuvant Therapy	NCT07244978	Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma	not yet recruiting	PHASE2	49
	NCT07086326	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	not yet recruiting	PHASE2	164
	NCT07359040	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	recruiting	N/A	80
	NCT06802666	Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer	recruiting	PHASE2	45
Pancreatic Cancer	NCT06953999	A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer	recruiting	PHASE3	999
	NCT06991491	Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)	not yet recruiting	PHASE2	29
	NCT06844422	Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)	recruiting	PHASE1/PHASE2	37
	NCT06491472	Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer	recruiting	PHASE2	36
Breast Cancer	NCT07560124	A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer	not yet recruiting	PHASE1/PHASE2	286
	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
AK112	NCT07162714	SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer	not yet recruiting	PHASE2	30
	NCT07086326	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	not yet recruiting	PHASE2	164
	NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	not yet recruiting	NA	36
Non Small Cell Lung Cancer	NCT07234877	Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets	not yet recruiting	PHASE2	158
	NCT06951646	ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)	recruiting	PHASE2	70
	NCT07208773	A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors	recruiting	PHASE1/PHASE2	260
Head and Neck Squamous Cell Carcinoma	NCT07381075	A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma	not yet recruiting	PHASE2	120
	NCT06814067	Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma	not yet recruiting	PHASE2	80
	NCT06444009	A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma	recruiting	PHASE2	90
Metastatic Colorectal Cancer	NCT07359456	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases	not yet recruiting	PHASE2	130
	NCT06959550	Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer	recruiting	PHASE2	90
Breast Tumors	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Biliary Tract Cancer	NCT06529718	Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients	recruiting	PHASE2	72
	NCT06993025	Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies	not yet recruiting	PHASE2	30
Advanced Solid Tumors	NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370
	NCT07208773	A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors	recruiting	PHASE1/PHASE2	260
Locally Advanced Breast Cancer	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
HER2-negative Breast Cancer	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
TNBC - Triple-Negative Breast Cancer	NCT07017673	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	recruiting	PHASE2	34
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Locally Advanced Rectal Cancer	NCT06760520	Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer	not yet recruiting	PHASE2	40
	NCT06802666	Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer	recruiting	PHASE2	45
Triple-Negative Breast Cancer (TNBC)	NCT06793332	BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC	recruiting	PHASE2	39
	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
Nasopharyngeal Carcinoma (NPC)	NCT07565389	Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma	not yet recruiting	PHASE2	42
	NCT07064902	Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma	not yet recruiting	PHASE2	48
HER2-positive Breast Cancer	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Hormone Receptor Negative Tumor	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Lung Cancer (NSCLC)	NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46
	NCT07472478	Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)	not yet recruiting	PHASE2	32
Small Cell Lung Cancer	NCT07208773	A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors	recruiting	PHASE1/PHASE2	260
	NCT06769971	Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC	recruiting	PHASE2	80
Hormone Receptor Positive Tumor	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Esophageal Squamous Cell Carcinoma	NCT07244978	Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma	not yet recruiting	PHASE2	49
	NCT07188103	Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma	recruiting	PHASE2	37
Early-stage Breast Cancer	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Immunotherapy	NCT07086326	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	not yet recruiting	PHASE2	164
	NCT07359040	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	recruiting	N/A	80
EGFR-TKI	NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	not yet recruiting	NA	36
Endometrial Cancer	NCT06925724	A Study of Ivonescimab in People With Endometrial and Cervical Cancers	recruiting	PHASE2	50
ESCC	NCT06489197	AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients	recruiting	PHASE2	30
Esophageal Squamour Cell Cancer	NCT06814158	Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer	not yet recruiting	PHASE2	57
Esophagus Cancer	NCT07070466	Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	recruiting	PHASE2	40
Extensive-stage Small-cell Lung Cancer	NCT06478043	A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC	not yet recruiting	PHASE2	54
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	NCT07245446	A Study of Ivonescimab in First-Line ES-SCLC	recruiting	PHASE2	180
Extensive Stage Lung Small Cell Cancer	NCT07057791	Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer	recruiting	PHASE2	60
First-line Treatment	NCT06750952	Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial	not yet recruiting	PHASE2	24
Gastric Adenocarcinoma	NCT06196697	AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer	recruiting	PHASE2	50
Gastric Cancer	NCT07374250	Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma	not yet recruiting	PHASE2	154
Gastroesophageal Junction Adenocarcinoma	NCT06196697	AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer	recruiting	PHASE2	50
Genomic Alterations	NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46
Glioblastoma	NCT06672575	A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma	recruiting	PHASE1/PHASE2	45
Head and Neck Squamous Cell Carcinoma HNSCC	NCT06814067	Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma	not yet recruiting	PHASE2	80
Hepatocellular Carcinoma	NCT06375486	Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.	recruiting	PHASE2	30
Hepatocellular Carcinoma Non-resectable	NCT06375486	Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.	recruiting	PHASE2	30
II-IIIB (T3N2) Resectable Non-small Cell Lung Cancer	NCT07241819	Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer	not yet recruiting	PHASE2	66
Immune Checkpoint Inhibitors (ICIs)	NCT06951646	ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)	recruiting	PHASE2	70
Ivonescimab	NCT06940518	Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma	recruiting	PHASE2	40
KRAS G12C	NCT07339839	Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC	not yet recruiting	PHASE1/PHASE2	42
KRAS G12C Lung Cancer	NCT07472478	Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)	not yet recruiting	PHASE2	32
Leiomyosarcoma	NCT07516925	A Study of Ivonescimab in People With Leiomyosarcoma	recruiting	PHASE2	20
Leptomeningeal Metastases	NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	not yet recruiting	NA	36
Localized Clear Cell Renal Cell Carcinoma	NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	recruiting	PHASE2	31
LOCALLY ADVANCED CERVICAL CANCERS	NCT07244965	Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer	not yet recruiting	PHASE2	42
Lung Cancer - Non Small Cell	NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46
Lung Cancer (Non-Small Cell)	NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46
Lung Cancer Non-Small Cell Cancer (NSCLC)	NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46
Lung Cancer Non Small Cell	NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46
Lung Squamous Cell Carcinoma	NCT07038915	STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1	withdrawn	PHASE2	0
Metastatic Breast Cancer ( HER2 Negative)	NCT07394218	ctDNA-guided Treatment Decision-making	recruiting	PHASE2	122
Metastatic Colorectal Cancer (CRC)	NCT07228832	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer	recruiting	PHASE3	600
Metastatic Endocrine Refractory	NCT07229417	IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma	recruiting	PHASE2	29
Metastatic Esophageal Adenocarcinoma	NCT06846346	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	recruiting	PHASE2	88
Metastatic Gastric Adenocarcinoma	NCT06846346	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	recruiting	PHASE2	88
Metastatic Microsatellite Stable Colorectal Carcinoma	NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	PHASE1	30
Metastatic Salivary Gland Cancer	NCT06805617	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	recruiting	PHASE2	35
Metastatic Solid Tumors	NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370
MSS/pMMR Type Metastatic Colorectal Adenocarcinoma Patients	NCT06936488	A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer	enrolling by invitation	NA	35
Multiple Advanced Tumors After PD-1 Therapy Failure	NCT07095803	Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure	not yet recruiting	PHASE2	60
Muscle-invasive Bladder Cancer	NCT06957561	Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	not yet recruiting	PHASE1/PHASE2	30
Non-small Cell Lung Cancer (NSCLC)	NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370
Non-Squamous Non-small Cell Lung Cancer	NCT05184712	Phase 3 Clinical Study of AK112 for NSCLC Patients	active not recruiting	PHASE3	322
Non Small Cell Lung Cancer (Stage III)	NCT07204548	The IVO-LUNG Study	not yet recruiting	PHASE2	63
NSCLC (Advanced Non-small Cell Lung Cancer)	NCT07158489	Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC	not yet recruiting	PHASE2	47
NSCLC Stage IV	NCT07339839	Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC	not yet recruiting	PHASE1/PHASE2	42
Pancreas Cancer	NCT06913218	A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC	not yet recruiting	PHASE1	60
Pancreas Cancer, Duct Cell Adenocarcinoma	NCT06913218	A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC	not yet recruiting	PHASE1	60
PD-1 Inhibitors	NCT07359040	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	recruiting	N/A	80
Perioperative	NCT07241819	Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer	not yet recruiting	PHASE2	66
Pleural Mesotheliomas	NCT06840834	Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy	recruiting	PHASE2	38
Precision Therapy	NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing	recruiting	PHASE2	39
Pretreated Pleural Mesothelioma	NCT06875076	Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma	recruiting	PHASE2	25
Radiation	NCT07162714	SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer	not yet recruiting	PHASE2	30
RCT	NCT07374250	Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma	not yet recruiting	PHASE2	154
Rectal Cancer	NCT07162714	SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer	not yet recruiting	PHASE2	30
Recurrent Lung Non-Small Cell Carcinoma	NCT07393555	Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)	not yet recruiting	PHASE2	117
Recurrent or Metastatic Nasopharyngeal Carcinoma	NCT07070479	Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial	recruiting	PHASE2	208
Relapsed or Metastatic Thymic Cancer	NCT06750952	Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial	not yet recruiting	PHASE2	24
Resectable Clear Cell Renal Cell Carcinoma	NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	recruiting	PHASE2	31
Resectable Head and Neck Squamous Cell Carcinoma	NCT07094685	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	recruiting	PHASE2	28
Salivary Gland Cancer	NCT06805617	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	recruiting	PHASE2	35
Salivary Gland Carcinoma	NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing	recruiting	PHASE2	39
SCLC	NCT06820762	Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study	not yet recruiting	PHASE2	40
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	NCT07264075	Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN	recruiting	PHASE3	780
Squamous Cell Lung Cancer	NCT07009925	Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.	not yet recruiting	PHASE2	38
Stage II Head and Neck Cutaneous Squamous Cell Carcinoma	NCT07094685	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	recruiting	PHASE2	28
Stage II Renal Cell Cancer AJCC v8	NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	recruiting	PHASE2	31
Stage III Colorectal Cancer AJCC v8	NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	PHASE1	30
Stage III Head and Neck Cutaneous Squamous Cell Carcinoma	NCT07094685	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	recruiting	PHASE2	28
Stage III Renal Cell Cancer AJCC v8	NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	recruiting	PHASE2	31
Stage IV Colorectal Cancer AJCC v8	NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	PHASE1	30
Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma	NCT07094685	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	recruiting	PHASE2	28
Stage IV Lung Cancer AJCC v8	NCT07393555	Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)	not yet recruiting	PHASE2	117
Stage IV Renal Cell Cancer AJCC v8	NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	recruiting	PHASE2	31
Stomach Cancer	NCT07070466	Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	recruiting	PHASE2	40
Stomach Cancer Stage IV	NCT07070466	Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	recruiting	PHASE2	40
Thymus Carcinoma	NCT06980077	Ivonescimab for the Treatment of Thymic Cancer	recruiting	PHASE2	25
TNBC	NCT07017673	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	recruiting	PHASE2	34
TNBC, Triple Negative Breast Cancer	NCT06977542	Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer	not yet recruiting	PHASE2	53
Adenoid Cystic Carcinoma	NCT06805617	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	recruiting	PHASE2	35
Triple Negative Invasive Lobular Carcinoma	NCT07229417	IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma	recruiting	PHASE2	29
Advanced Esophageal Adenocarcinoma	NCT06846346	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	recruiting	PHASE2	88
Advanced Esophageal Squamous Cell Carcinoma	NCT06489197	AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients	recruiting	PHASE2	30
Advanced Gastric Adenocarcinoma	NCT06846346	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	recruiting	PHASE2	88
Advanced Head and Neck Squamous Cell Carcinoma	NCT07094685	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	recruiting	PHASE2	28
Advanced Malignant Tumors	NCT06877650	First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors	recruiting	PHASE1/PHASE2	436
Advanced Microsatellite Stable Colorectal Carcinoma	NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	PHASE1	30
Advanced Non-small Cell Lung Cancer	NCT06868732	Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC	recruiting	PHASE1	288
Advanced Salivary Gland Carcinoma	NCT06805617	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	recruiting	PHASE2	35
Angiosarcoma	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Anti-PD1/PDL1 Antibody	NCT07038915	STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1	withdrawn	PHASE2	0
Bispecific Antibody	NCT07086326	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	not yet recruiting	PHASE2	164
Bladder Cancer	NCT06957561	Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	not yet recruiting	PHASE1/PHASE2	30
Brain Metastases	NCT06793332	BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC	recruiting	PHASE2	39
Breast Neoplasm	NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716
Breast Neoplasms	NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000
Cervical Cancer	NCT06925724	A Study of Ivonescimab in People With Endometrial and Cervical Cancers	recruiting	PHASE2	50
Chemotherapy	NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	not yet recruiting	NA	36
Clear Cell Renal Carcinoma	NCT06940518	Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma	recruiting	PHASE2	40
Colon Cancer	NCT06790212	Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer	not yet recruiting	PHASE2	168
Colorectal Cancer (CRC)	NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370
Colorectal Liver Metastases	NCT06848842	Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases	recruiting	PHASE2	40
CRC	NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370
ctDNA	NCT07394218	ctDNA-guided Treatment Decision-making	recruiting	PHASE2	122
Cutaneous Squamous Cell Carcinoma	NCT06567314	Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma	recruiting	PHASE2	24
Early Stage Triple-Negative Breast Carcinoma	NCT07017673	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	recruiting	PHASE2	34

All Ivonescimab Clinical Trials (87)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07393555	Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)	not yet recruiting	PHASE2	117	SWOG Cancer Research Network
NCT07405190	Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC	not yet recruiting	PHASE2	46	Massachusetts General Hospital
NCT07158489	Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC	not yet recruiting	PHASE2	47	Swiss Cancer Institute
NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	PHASE1	30	City of Hope Medical Center
NCT07226544	Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer	recruiting	PHASE2	31	City of Hope Medical Center
NCT07560124	A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer	not yet recruiting	PHASE1/PHASE2	286	Akeso
NCT07244978	Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma	not yet recruiting	PHASE2	49	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07565389	Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma	not yet recruiting	PHASE2	42	National University Hospital, Singapore
NCT07412262	A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression	not yet recruiting	PHASE2	32	Guangdong Association of Clinical Trials
NCT07234877	Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets	not yet recruiting	PHASE2	158	European Organisation for Research and Treatment of Cancer - EORTC
NCT07264075	Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN	recruiting	PHASE3	780	Groupe Oncologie Radiotherapie Tete et Cou
NCT07535463	A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer	recruiting	PHASE1/PHASE2	53	Memorial Sloan Kettering Cancer Center
NCT07535437	A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer	recruiting	PHASE1/PHASE2	66	Memorial Sloan Kettering Cancer Center
NCT07516925	A Study of Ivonescimab in People With Leiomyosarcoma	recruiting	PHASE2	20	Memorial Sloan Kettering Cancer Center
NCT07359456	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases	not yet recruiting	PHASE2	130	UNICANCER
NCT07057791	Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer	recruiting	PHASE2	60	PrECOG, LLC.
NCT07472478	Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)	not yet recruiting	PHASE2	32	Guangdong Provincial People's Hospital
NCT06951646	ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)	recruiting	PHASE2	70	Second Xiangya Hospital of Central South University
NCT07339839	Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC	not yet recruiting	PHASE1/PHASE2	42	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07374250	Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma	not yet recruiting	PHASE2	154	Sichuan University
NCT07381075	A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma	not yet recruiting	PHASE2	120	West China Hospital
NCT07397338	Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors	recruiting	PHASE1/PHASE2	370	Revolution Medicines, Inc.
NCT07394218	ctDNA-guided Treatment Decision-making	recruiting	PHASE2	122	Fudan University
NCT07244965	Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer	not yet recruiting	PHASE2	42	Women's Hospital School Of Medicine Zhejiang University
NCT07241819	Ivonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung Cancer	not yet recruiting	PHASE2	66	Peking University Cancer Hospital & Institute
NCT06846346	Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma	recruiting	PHASE2	88	UNICANCER
NCT07228832	Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer	recruiting	PHASE3	600	Summit Therapeutics
NCT07094685	Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer	recruiting	PHASE2	28	University of Michigan Rogel Cancer Center
NCT07204548	The IVO-LUNG Study	not yet recruiting	PHASE2	63	Sun Yat-sen University
NCT07245446	A Study of Ivonescimab in First-Line ES-SCLC	recruiting	PHASE2	180	Akeso
NCT07208773	A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors	recruiting	PHASE1/PHASE2	260	MediLink Therapeutics (Suzhou) Co., Ltd.
NCT07229417	IvoLoC Trial: A Phase II Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular Carcinoma	recruiting	PHASE2	29	M.D. Anderson Cancer Center
NCT07070466	Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA	recruiting	PHASE2	40	Massachusetts General Hospital
NCT06529718	Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients	recruiting	PHASE2	72	UNICANCER
NCT06848842	Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases	recruiting	PHASE2	40	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT07162714	SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer	not yet recruiting	PHASE2	30	Zhejiang Cancer Hospital
NCT07064902	Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma	not yet recruiting	PHASE2	48	Sun Yat-sen University
NCT07095803	Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure	not yet recruiting	PHASE2	60	Sheng Zhang
NCT07086326	A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC	not yet recruiting	PHASE2	164	Yang Fan, MD
NCT07038915	STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1	withdrawn	PHASE2	0	M.D. Anderson Cancer Center
NCT06959550	Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer	recruiting	PHASE2	90	M.D. Anderson Cancer Center
NCT07017673	Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer	recruiting	PHASE2	34	Cedars-Sinai Medical Center
NCT06913218	A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC	not yet recruiting	PHASE1	60	Akeso
NCT06980077	Ivonescimab for the Treatment of Thymic Cancer	recruiting	PHASE2	25	Jonsson Comprehensive Cancer Center
NCT06928389	Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer	recruiting	PHASE3	536	Akeso
NCT06940518	Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma	recruiting	PHASE2	40	M.D. Anderson Cancer Center
NCT07188103	Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma	recruiting	PHASE2	37	Anhui Provincial Hospital
NCT07359040	Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer	recruiting	N/A	80	Peking University People's Hospital
NCT06840834	Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy	recruiting	PHASE2	38	Intergroupe Francophone de Cancerologie Thoracique
NCT06977542	Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer	not yet recruiting	PHASE2	53	Fudan University
NCT07009925	Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.	not yet recruiting	PHASE2	38	Jiangsu Cancer Institute & Hospital
NCT07070479	Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial	recruiting	PHASE2	208	Ming-Yuan Chen
NCT06953999	A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer	recruiting	PHASE3	999	Akeso
NCT06991491	Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)	not yet recruiting	PHASE2	29	West China Hospital
NCT06993025	Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies	not yet recruiting	PHASE2	30	Tianjin Medical University Cancer Institute and Hospital
NCT06957561	Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	not yet recruiting	PHASE1/PHASE2	30	Sun Yat-sen University
NCT06790212	Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer	not yet recruiting	PHASE2	168	Sun Yat-sen University
NCT06877650	First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors	recruiting	PHASE1/PHASE2	436	Shanghai JMT-Bio Inc.
NCT06925724	A Study of Ivonescimab in People With Endometrial and Cervical Cancers	recruiting	PHASE2	50	Memorial Sloan Kettering Cancer Center
NCT06868732	Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC	recruiting	PHASE1	288	Jiangsu Alphamab Biopharmaceuticals Co., Ltd
NCT06875076	Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma	recruiting	PHASE2	25	The First Hospital of Jilin University
NCT06814158	Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer	not yet recruiting	PHASE2	57	Tianjin Medical University Cancer Institute and Hospital
NCT06936488	A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer	enrolling by invitation	NA	35	Huai'an First People's Hospital
NCT06820762	Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study	not yet recruiting	PHASE2	40	The Second Affiliated Hospital of Dalian Medical University
NCT06767514	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1	recruiting	PHASE3	780	Summit Therapeutics
NCT06805617	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers	recruiting	PHASE2	35	Glenn J. Hanna
NCT06814067	Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma	not yet recruiting	PHASE2	80	Fudan University
NCT06844422	Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)	recruiting	PHASE1/PHASE2	37	Shandong Cancer Hospital and Institute
NCT06769971	Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC	recruiting	PHASE2	80	Sichuan University
NCT06672575	A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma	recruiting	PHASE1/PHASE2	45	M.D. Anderson Cancer Center
NCT06760520	Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer	not yet recruiting	PHASE2	40	The First Affiliated Hospital of Zhengzhou University
NCT06766591	Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs	not yet recruiting	NA	36	Jiangsu Province Nanjing Brain Hospital
NCT06750952	Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial	not yet recruiting	PHASE2	24	Sun Yat-sen University
NCT06793332	BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC	recruiting	PHASE2	39	Fudan University
NCT06567314	Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma	recruiting	PHASE2	24	M.D. Anderson Cancer Center
NCT06489197	AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients	recruiting	PHASE2	30	Tianjin Medical University Cancer Institute and Hospital
NCT06802666	Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer	recruiting	PHASE2	45	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06478043	A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC	not yet recruiting	PHASE2	54	Zhejiang Cancer Hospital
NCT06491472	Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer	recruiting	PHASE2	36	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06444009	A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma	recruiting	PHASE2	90	Lei Liu
NCT06196697	AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer	recruiting	PHASE2	50	Harbin Medical University
NCT06375486	Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma（uHCC）.	recruiting	PHASE2	30	Tianjin Medical University Cancer Institute and Hospital
NCT05899608	Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients	recruiting	PHASE3	1,600	Summit Therapeutics
NCT06145308	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing	recruiting	PHASE2	39	Peking Union Medical College
NCT05582499	Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy	recruiting	PHASE2	716	Fudan University
NCT05184712	Phase 3 Clinical Study of AK112 for NSCLC Patients	active not recruiting	PHASE3	322	Akeso
NCT01042379	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	recruiting	PHASE2	5,000	QuantumLeap Healthcare Collaborative

Where to Participate: All Ivonescimab Trial Sites in the U.S. (311 sites across 40 states)

Every actively recruiting Ivonescimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT01042379	Map
AZ	Clinical Study Site	Chandler85224	NCT06767514	Map
AZ	Clinical Study Site	Goodyear85338	NCT07228832	Map
AZ	Banner University Medical Center	Phoenix85006	NCT05899608	Map
AZ	Clinical Study Site	Phoenix85006	NCT06767514	Map
AZ	TMC Healthcare	Tucson85711	NCT05899608	Map
AR	Clinical Study Site	Hot Springs71913	NCT06767514	Map
AR	Genesis Cancer and Blood Institute	Hot Springs71913	NCT05899608	Map
AR	University of Arkansas	Little Rock72205	NCT05899608	Map
CA	LA Cancer Network	Anaheim92801	NCT05899608	Map
CA	Clinical Study Site	Beverly Hills90211	NCT07228832	Map
CA	Clinical Study Site	Beverly Hills90212	NCT07228832	Map
CA	Clinical Study Site	Cerritos90703	NCT06767514	Map
CA	Clinical Study Site	Cerritos90703	NCT07228832	Map
CA	The Oncology Institute of Hope & Innovation	Cerritos90703	NCT05899608	Map
CA	Clinical Study Site	Corona92882	NCT07228832	Map
CA	University of California - Davis, Comprehensive Cancer Center	Davis95817	NCT01042379	Map
CA	City of Hope	Duarte91010	NCT01042379	Map
CA	City of Hope Medical Center	Duarte91010	NCT07226544	Map
CA	Clinical Study Site	Duarte91010	NCT07228832	Map
CA	Clinical Study Site	Fountain Valley92708	NCT07228832	Map
CA	Clinical Study Site	Glendale91204	NCT06767514	Map
CA	Clinical Study Site	Huntington Beach92648	NCT07228832	Map
CA	Clinical Study Site	Irvine92612	NCT06767514	Map
CA	Clinical Study Site	Irvine92612	NCT07228832	Map
CA	Clinical Study Site	Irvine92618	NCT07228832	Map
CA	University of California San Diego	La Jolla92093-0698	NCT01042379	Map
CA	Cedar Sinai Medical Center	Los Angeles90048	NCT05899608	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT07017673	Map
CA	Cedars-Sinai Medical Center Beverly Hills	Los Angeles90211	NCT07017673	Map
CA	Clinical Study Site	Los Angeles90067	NCT06767514	Map
CA	Clinical Study Site	Los Angeles90027	NCT07228832	Map
CA	Clinical Study Site	Los Angeles90067	NCT07228832	Map
CA	Clinical Study Site	Los Angeles90404	NCT07228832	Map
CA	UCLA / Jonsson Comprehensive Cancer Center	Los Angeles90095	NCT06980077	Map
CA	University of Southern California	Los Angeles90033	NCT01042379	Map
CA	University of Southern California (USC)	Los Angeles90033	NCT05899608	Map
CA	Valkyrie Clinical Trials	Los Angeles90067	NCT05899608	Map
CA	Clinical Study Site	Mountain View94040	NCT06767514	Map
CA	Clinical Study Site	Murrieta92562	NCT06767514	Map
CA	Clinical Study Site	Murrieta92562	NCT07228832	Map
CA	Clinical Study Site	Newport Beach92663	NCT06767514	Map
CA	HOAG Memorial Hospital Presbyterian	Newport Beach92663	NCT01042379	Map
CA	Clinical Study Site	Orange92868	NCT07228832	Map
CA	Clinical Study Site	Pasadena91030	NCT07228832	Map
CA	Clinical Study Site	Roseville95661	NCT06767514	Map
CA	Clinical Study Site	Sacramento95816	NCT06767514	Map
CA	Sutter Institute for Medical Research	Sacramento95816	NCT05899608	Map
CA	UC Davis Medical Center	Sacramento95817	NCT05899608	Map
CA	Clinical Study Site	San Diego92123	NCT06767514	Map
CA	Clinical Study Site	San Francisco94115	NCT06767514	Map
CA	University of California at San Francisco (UCSF)	San Francisco94115	NCT06980077	Map
CA	University of California San Francisco (UCSF)	San Francisco94115	NCT01042379	Map
CA	Clinical Study Site	Santa Ana92705	NCT06767514	Map
CA	UCLA	Santa Monica90404	NCT07070466	Map
CA	University of California Los Angeles (UCLA)	Santa Monica90404	NCT05899608	Map
CA	Providence Medical Foundation	Santa Rosa95403	NCT05899608	Map
CA	Clinical Study Site	Torrance90503	NCT07228832	Map
CA	Hunt Cancer Institute, an Affiliate of CS Cancer	Torrance90505	NCT07017673	Map
CA	Clinical Study Site	Upland91786	NCT07228832	Map
CA	Kaiser Permanente	Vallejo94589	NCT05899608	Map
CA	Clinical Study Site	West Hollywood90048	NCT07228832	Map
CA	Clinical Study Site	Whittier90602	NCT06767514	Map
CO	Clinical Study Site	Aurora80045	NCT06767514	Map
CO	University of Colorado Cancer Center	Aurora80045	NCT01042379	Map
CO	Clinical Study Site	Grand Junction81505	NCT06767514	Map
CO	Clinical Study Site	Greeley80631	NCT06767514	Map
CO	Clinical Study Site	Lone Tree80124	NCT06767514	Map
CO	Rocky Mountain Cancer	Lone Tree80124	NCT05899608	Map
CO	Banner MD Anderson Cancer Center at North Colorado Medical Center	Loveland80538	NCT05899608	Map
CO	Clinical Study Site	Loveland80538	NCT06767514	Map
CT	Clinical Study Site	Hartford06106	NCT07228832	Map
CT	Hartford Hospital	Hartford06053	NCT05899608	Map
CT	Clinical Study Site	New Haven06520-8028	NCT07228832	Map
CT	Yale Cancer Center	New Haven06510	NCT01042379	Map
CT	Yale University	New Haven06510	NCT05899608	Map
CT	Clinical Study Site	Norwich06360	NCT07228832	Map
CT	Eastern Connecticut Hematology and Oncology Associates	Norwich06360	NCT07397338	Map
DC	Georgetown University Medical Center	Washington D.C.20007	NCT01042379	Map
FL	Clinical Study Site	Fort Lauderdale33317	NCT06767514	Map
FL	Florida Cancer Specialists & Research Institute (FCS)-East	Fort Myers33901	NCT05899608	Map
FL	BioResearch Partner- Hialeah Hospital	Hialeah33013	NCT05899608	Map
FL	Clinical Study Site	Hialeah33013	NCT06767514	Map
FL	Clinical Study Site	Hialeah33013	NCT07228832	Map
FL	Cancer Specialists of North Florida	Jacksonville32256	NCT05899608	Map
FL	Clinical Study Site	Jacksonville32256	NCT06767514	Map
FL	Mayo Clinic	Jacksonville32224	NCT05899608	Map
FL	Clinical Study Site	Miami33155	NCT06767514	Map
FL	Clinical Study Site	Miami33176	NCT07228832	Map
FL	Clinical Study Site	North Venice34275	NCT06767514	—
FL	Ocala Oncology	Ocala34474	NCT05899608	Map
FL	Clinical Study Site	Orlando32822	NCT06767514	Map
FL	Clinical Study Site	Orlando32806	NCT07228832	Map
FL	Cancer Care of Brevard	Palm Bay32901	NCT05899608	Map
FL	Memorial Cancer Institute	Pembroke Pines33028	NCT05899608	Map
FL	Ascension Sacred Heart Health System	Pensacola32504	NCT05899608	Map
FL	Clinical Study Site	Pensacola32504	NCT06767514	Map
FL	BRCR Medical Center Inc	Plantation33322	NCT05899608	Map
FL	Clinical Study Site	Plantation33322	NCT06767514	Map
FL	Clinical Study Site	Plantation33323	NCT06767514	Map
FL	Clinical Study Site	Plantation33322	NCT07228832	Map
FL	Clinical Study Site	Port Saint Lucie34952	NCT07228832	Map
FL	Exigent Network	St. Petersburg33709	NCT05899608	Map
FL	Florida Cancer Specialists & Research Institute (FCS) - North	St. Petersburg33705	NCT05899608	Map
FL	Clinical Study Site	Tallahassee32308	NCT06767514	Map
FL	BRCR Medical Center Inc.	Tamarac33321	NCT05899608	Map
FL	Clinical Study Site	Tamarac33321	NCT06767514	Map
FL	Clinical Study Site	Tamarac33321	NCT07228832	Map
FL	H. Lee Moffitt Cancer Center and Research Institute	Tampa33612	NCT01042379	Map
FL	Moffitt Cancer Center	Tampa33612	NCT01042379	Map
FL	Clinical Study Site	West Palm Beach33401	NCT06767514	Map
FL	Florida Cancer Specialists & Research Institute (FCS)-South	West Palm Beach33401	NCT05899608	Map
GA	Clinical Study Site	Atlanta30318	NCT06767514	Map
GA	Winship Cancer Institute of Emory University	Atlanta30322	NCT01042379	Map
GA	Central Georgia Cancer Care	Macon31210	NCT05899608	Map
GA	Clinical Study Site	Macon30318	NCT06767514	Map
GA	Clinical Study Site	Macon31210	NCT06767514	Map
GA	Clinical Study Site	Newnan30265	NCT07228832	Map
IL	Clinical Study Site	Carterville62918	NCT06767514	Map
IL	Clinical Study Site	Chicago60611	NCT07228832	Map
IL	Northwestern Memorial Hospital	Chicago60611	NCT05899608	Map
IL	University of Chicago	Chicago60453	NCT01042379	Map
IL	Clinical Study Site	Elmhurst60540	NCT07228832	Map
IL	Loyola University	Maywood60153	NCT01042379	Map
IL	Clinical Study Site	O'Fallon62269	NCT07228832	Map
IL	Illinois Cancer Care	Peoria61615	NCT05899608	Map
IN	Clinical Study Site	Fort Wayne46804	NCT07228832	Map
IN	Clinical Study Site	Indianapolis46237	NCT06767514	Map
IN	Clinical Study Site	Indianapolis46202	NCT07228832	Map
IA	Clinical Study Site	Waukee50263	NCT06767514	Map
KS	University of Kansas Cancer Center	Westwood66205	NCT05899608	Map
KY	Clinical Study Site	Edgewood41017	NCT07228832	Map
KY	Baptist Health	Lexington40503	NCT05899608	Map
KY	Clinical Study Site	Lexington40503	NCT06767514	Map
LA	Clinical Study Site	Covington70433	NCT06767514	Map
MD	Ascension Saint Agnes Hospital	Baltimore21229	NCT05899608	Map
MD	Clinical Study Site	Baltimore21229	NCT06767514	Map
MD	Sidney Kimmel Comprehensive Cancer Center	Baltimore21187	NCT05899608	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06805617	Map
MA	Clinical Study Site	Boston02215	NCT06767514	Map
MA	Dana-Farber Cancer Institute	Boston02115	NCT06805617	Map
MA	Massachusetts General Hospital	Boston02114	NCT07070466	Map
MA	Lahey Hospital	Burlington01805	NCT05899608	Map
MA	Clinical Study Site	Milton02186	NCT06767514	Map
MA	Clinical Study Site	Worcester01655	NCT06767514	Map
MI	Trinity Health	Ann Arbor48197	NCT05899608	Map
MI	University of Michigan	Ann Arbor48109	NCT05899608	Map
MI	University of Michigan Comprehensive Cancer Center	Ann Arbor48109	NCT07094685	Map
MI	Clinical Study Site	Detroit48202	NCT06767514	Map
MI	Clinical Study Sites	Detroit48202	NCT06767514	Map
MI	Henry Ford Hospital	Detroit48202	NCT05899608	Map
MI	Karmanos Cancer Insitute	Detroit48201	NCT05899608	Map
MI	Clinical Study Site	Lansing48910	NCT06767514	Map
MI	Herbert-Herman Cancer Center, Sparrow Hospital	Lansing48912	NCT01042379	Map
MN	Clinical Study Site	Minneapolis55455	NCT06767514	Map
MN	University of Minnesota	Minneapolis55455	NCT01042379	Map
MN	Mayo Clinic	Rochester55905	NCT05899608	Map
MN	Mayo Clinic	Rochester55905	NCT01042379	Map
MN	Clinical Study Site	Saint Louis Park55426	NCT06767514	Map
MN	Clinical Study Site	Saint Louis Park55426	NCT07228832	Map
MN	Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center	Saint Louis Park55416	NCT01042379	Map
MN	Clinical Study Site	Saint Paul55101	NCT06767514	Map
MN	Park Nicollet Institute	Saint Paul55101	NCT05899608	Map
MS	Clinical Study Site	Hattiesburg39401	NCT06767514	Map
MO	American Oncology Partners, PA	Kansas City64132	NCT05899608	Map
MO	Clinical Study Site	Kansas City64132	NCT06767514	Map
MO	Clinical Study Site	St Louis63128	NCT06767514	Map
MO	Washington University St.Louis	St Louis63110	NCT05899608	Map
MT	Clinical Study Site	Billings59102	NCT07228832	Map
MT	St. Vincent Cancer Center	Billings59102	NCT05899608	Map
NE	Clinical Study Site	Lincoln68506	NCT07228832	Map
NE	University of Nebraska Medical Center (UNMC)	Omaha68105	NCT05899608	Map
NH	Clinical Study Site	Lebanon03756	NCT06767514	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT05899608	Map
NJ	Clinical Study Site	Basking Ridge07920	NCT06767514	Map
NJ	Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)	Basking Ridge07920	NCT07516925	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT06925724	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT07535437	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT07535463	Map
NJ	Clinical Study Site	Middletown07748	NCT06767514	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT06925724	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT07535437	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT07535463	Map
NJ	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown07748	NCT07516925	Map
NJ	Clinical Study Site	Montvale07645	NCT06767514	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT06925724	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT07535437	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT07535463	Map
NJ	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale07645	NCT07516925	Map
NJ	Clinical Study Site	Mullica Hill08062	NCT06767514	Map
NJ	Clinical Study Site	New Brunswick08901	NCT06767514	Map
NJ	Clinical Study Site	New Brunswick08901	NCT07228832	Map
NJ	Rutgers Cancer Institute	New Brunswick08901	NCT07057791	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08903	NCT01042379	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT01042379	Map
NY	Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)	Commack11725	NCT07535437	Map
NY	Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)	Commack11725	NCT07535463	Map
NY	Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)	Commack11725	NCT07516925	Map
NY	Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities)	Commack11725	NCT06925724	Map
NY	Clinical Study Site	Glen Falls12801	NCT06767514	—
NY	Clinical Study Site	Harrison10604	NCT06767514	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT06925724	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT07535437	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT07535463	Map
NY	Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison10604	NCT07516925	Map
NY	Clinical Study Site	Mineola11501	NCT07228832	Map
NY	Clinical Study Site	New York10065	NCT06767514	Map
NY	Clinical Study Site	New York10016	NCT07228832	Map
NY	Columbia University Medical Center	New York10032	NCT01042379	Map
NY	Laura and Isaac Perlmutter Cancer Center / NYU Langone Health	New York10016	NCT01042379	Map
NY	Memorial Sloan Kettering	New York10065	NCT05899608	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07516925	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT06925724	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07535437	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT07535463	Map
NY	Mount Sinai	New York10029	NCT05899608	Map
NY	University of Rochester Wilmot Cancer Institute	Rochester14642	NCT01042379	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Rockville Centre11553	NCT07535463	Map
NY	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Rockville Centre11553	NCT07516925	Map
NY	Clinical Study Site	Syracuse13210	NCT06767514	Map
NY	SUNY Upstate Medical University	Syracuse13210	NCT05899608	Map
NY	Clinical Study Site	The Bronx10461	NCT07228832	Map
NY	Montefiore Medical Center	The Bronx10467	NCT01042379	Map
NY	Montefiore Medical Center- Montefiore Medical Park	The Bronx10461	NCT07057791	Map
NY	Clinical Study Site	Uniondale11553	NCT06767514	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale11553	NCT06925724	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale11553	NCT07535437	Map
NC	Clinical Study Site	Chapel Hill27592	NCT06767514	Map
NC	University of North Carolina	Chapel Hill27514	NCT05899608	Map
NC	Levine Center	Charlotte28204	NCT05899608	Map
NC	Wake Forest Baptist Comprehensive Cancer Center	Winston-Salem27157	NCT01042379	Map
OH	Clinical Study Site	Akron44032	NCT07228832	Map
OH	Clinical Study Site	Canton44703	NCT07228832	Map
OH	Clinical Study Site	Cincinnati45219	NCT07228832	Map
OH	Clinical Study Site	Cincinnati45220	NCT07228832	Map
OH	Oncology Hematology Care (OHC), Inc	Cincinnati45242	NCT05899608	Map
OH	Cleveland Clinic	Cleveland44195	NCT05899608	Map
OH	Cleveland Clinic	Cleveland44106	NCT01042379	Map
OH	Clinical Study Site	Cleveland44111	NCT07228832	Map
OH	Clinical Study Site	Cleveland44195	NCT07228832	Map
OH	University Hospitals Case Medical Center	Cleveland44106	NCT05899608	Map
OH	Clinical Study Site	Columbus43219	NCT06767514	Map
OH	The Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT01042379	Map
OH	Clinical Study Sites	Lebanon45036	NCT06767514	Map
OH	Clinical Study Site	Mayfield Heights44124	NCT07228832	Map
OK	Clinical Study Site	Oklahoma City73102	NCT06767514	Map
OR	Clinical Study Site	Eugene97401	NCT06767514	Map
OR	Willamette Valley Cancer Institute and Research Center (WVCI)	Eugene97401	NCT05899608	Map
OR	Clinical Study Site	Portland97239	NCT06767514	Map
OR	Oregon Health & Science Institute (OHSU)	Portland97239	NCT01042379	Map
PA	Clinical Study Site	Philadelphia19111	NCT06767514	Map
PA	Clinical Study Site	Philadelphia19111	NCT07228832	Map
PA	Clinical Study Site	Philadelphia19140	NCT07228832	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT07057791	Map
PA	University of Pennsylvania (U Penn)	Philadelphia19104	NCT01042379	Map
PA	Clinical Study Site	Pittsburgh15232	NCT06767514	Map
PA	Guthrie	Sayre18840	NCT07057791	Map
SC	Medical University of South Carolina (MUSC)	Charleston29425	NCT05899608	Map
SC	Prisma Health-Upstate	Greenville29605	NCT05899608	Map
SD	Sanford Clinical Research	Sioux Falls57104	NCT01042379	Map
TN	Clinical Study Site	Hermitage37129	NCT07228832	Map
TN	West Cancer Center	Memphis38138	NCT05899608	Map
TN	Clinical Study Site	Nashville37235	NCT06767514	Map
TN	SCRI-Nashville	Nashville37203	NCT05899608	Map
TN	Tennessee Oncology	Nashville37023	NCT07397338	Map
TX	Clinical Study Site	Abilene79601	NCT06767514	Map
TX	Clinical Study Site	Austin78745	NCT06767514	Map
TX	Texas Oncology- Austin	Austin78745	NCT05899608	Map
TX	Clinical Study Site	Dallas75246	NCT06767514	Map
TX	Texas Oncology-Dallas	Dallas75246	NCT05899608	Map
TX	UT Southwestern Medical Center	Dallas75390	NCT05899608	Map
TX	Clinical Study Site	Fort Worth76104	NCT07228832	Map
TX	Clinical Study Site	Forth Worth76104	NCT06767514	—
TX	Clinical Study Site	Houston77030	NCT06767514	Map
TX	Houston Methodist Hospital	Houston77030	NCT05899608	Map
TX	MD Anderson Cancer Center	Houston77030	NCT05899608	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06567314	Map
TX	MD Anderson Cancer Center	Houston77030	NCT06940518	Map
TX	MD Anderson Cancer Center	Houston77030	NCT07229417	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06672575	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06959550	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06672575	Map
TX	NEXT Dallas	Irving75039	NCT07397338	Map
TX	NEXT Oncology	San Antonio78229	NCT07397338	Map
TX	Texas Oncology-San Antonio	San Antonio78216	NCT05899608	Map
TX	Clinical Study Site	Tyler75708	NCT06767514	Map
TX	Texas Oncology-Tyler	Tyler75702	NCT05899608	Map
TX	University of Texas at Tyler	Tyler75708	NCT05899608	Map
TX	Clinical Study Site	Webster77598	NCT06767514	Map
UT	Clinical Study Site	Salt Lake City84106	NCT06767514	Map
UT	Clinical Study Site	Salt Lake City84106	NCT07228832	Map
UT	Huntsman Cancer Institute, University of Utah	Salt Lake City84112	NCT01042379	Map
VA	Clinical Study Site	Blacksburg24060	NCT06767514	Map
VA	Clinical Study Site	Charlottesville22908	NCT06767514	Map
VA	Clinical Study Site	Charlottesville22908	NCT07228832	Map
VA	Universtiy of Virginia	Charlottesville22908	NCT07057791	Map
VA	Clinical Study Site	Fairfax22031	NCT06767514	Map
VA	NEXT Virginia	Fairfax22031	NCT07397338	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT05899608	Map
VA	Virginia Cancer	Reston20190	NCT05899608	Map
VA	Clinical Study Site	Richmond23229	NCT06767514	Map
VA	Clinical Study Site	Richmond23298	NCT06767514	Map
WA	Clinical Study Site	Seattle98109	NCT06767514	Map
WA	Swedish Cancer Institute	Seattle98103	NCT05899608	Map
WA	Cancer Care NW Centers	Spokane99202	NCT05899608	Map
WA	Clinical Study Site	Spokane99208	NCT07228832	Map
WA	Clinical Study Site	Tacoma98405	NCT07228832	Map
WA	Clinical Study Site	Vancouver98684	NCT06767514	Map
WV	Clinical Study Site	Charleston25304	NCT07228832	Map
WI	Carbone Cancer Center	Madison53792	NCT05899608	Map
WI	Aspirus Cancer Center Wausau	Wausau54401	NCT07057791	Map

Browse Ivonescimab Trials by State

California clinical trials Texas clinical trials New York clinical trials New Jersey clinical trials Pennsylvania clinical trials Ohio clinical trials Florida clinical trials Tennessee clinical trials Massachusetts clinical trials Washington clinical trials

ivonescimabnon-small cell lung cancernsclcneoadjuvant therapypancreatic cancerbreast cancerclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated May 14, 2026.

What Is Ivonescimab?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Ivonescimab Development Timeline

Conditions Under Study

All Ivonescimab Clinical Trials (87)

Sponsors

Where to Participate: All Ivonescimab Trial Sites in the U.S. (311 sites across 40 states)

Browse Ivonescimab Trials by State